AIT Therapeutics, Inc. (OTCMKTS:KKICD) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On January 26, 2017, the Board of Directors (the Board) of
AIT Therapeutics, Inc., a Delaware corporation (the
Company), appointed Mr. Hai Aviv to serve as the Companys
Chief Financial Officer, effective as of February 28, 2017.

Mr. Aviv, who is 35 years old, will join the Company from Babylon
Ltd., a publicly-traded Israeli company listed on the Tel Aviv
Stock Exchange, operating in the fields of Internet, risk capital
investments and software, where he has served as Chief Financial
Officer from 2013 to the present. From 2010 to 2013, Mr. Aviv
served as Babylons corporate controller. Mr. Aviv is a certified
public accountant and, from 2005 to 2010, served as manager at
the Ernst Young Accounting Firm, Kost Forer, Gabbay Kasierer,
working predominantly with the high-tech team.

In connection with Mr. Avivs appointment as CFO, Mr. Aviv entered
into an employment agreement (the Employment Agreement)
with the Companys wholly owned subsidiary, Advanced Inhalation
Therapies, Ltd., providing for annual compensation in an amount
equal to 420,000 New Israeli Shekels (NIS), or approximately
$113,400, based on an exchange rate of $0.27 per NIS. Severance
and disability benefits are generally provided as required under
Israeli law. Additionally, Mr. Aviv is entitled to a grant of
options to purchase 50,000 shares of the Companys common stock,
par value $0.0001, per share, subject to the Boards adoption of
an equity compensation plan and due authorization of such grant.
Under the Employment Agreement, Mr. Aviv has also agreed to
customary non-disclosure and non-competition covenants, and
either party may terminate the Employment agreement upon 90-days
prior written notice to the non-terminating party. The foregoing
description of the Employment Agreement is only a summary and is
qualified in its entirety by reference to the complete text of
the Employment Agreement, a copy of which is filed as Exhibit
10.1 to this Current Report on form 8-K and incorporated by
reference in this Item 5.02.

Other than as described in this Current Report on Form 8-K, there
are no arrangements or understandings between Mr. Aviv and any
other person to which Mr. Aviv was selected as an officer of the
Company. Since the beginning of the Companys last fiscal year,
the Company has not engaged in any transaction, or any currently
proposed transaction, in which Mr. Aviv had or will have a direct
or indirect material interest in which the amount involved
exceeded or would exceed $120,000.

ITEM 9.01 Financial Statements and Exhibits.

(d) Exhibits